natgillin/translations-raw huggingface dataset:
A lighting module of claim 1, wherein said microchip is configured to operate the switching device such that 330 mA to 450 mA is delivered to the light emitting diode when said thermistor senses between 80°C to 100°C. 
Rasvjetni modul iz patentnog zahtjeva 1, naznačen time, da je navedeni mikročip konfiguriran da upravlja preklopnim sklopom tako da se LED diodi isporučuje 330 mA do 450 mA kada navedeni termistor odčita temperaturu u rasponu 80% do 100 "€.
The system of claim 13, wherein the second software module, configured to determine a likelihood of repairing the invalid field of the portable executable file, is configured to determine the number and characteristics of the attributes of the invalid field that do not match a valid characteristic of a valid corresponding field based upon, at least in part, a portable executable file format specification. 
Sustav u skladu s patentnim zahtjevom 11, naznačen time što dodatno sadrži sedmi programski modul, kojeg može izvršiti procesor s memorijom, gdje je sedmi programski modul konfiguriran za pokretanje postupka uklanjanja pogrešaka, uključujući pokretanje postupka uklanjanja pogrešaka na osnovi, u najmanju ruku djelomično, pakirane prijenosne izvršne datoteke.
The aerosol composition may be free from excipients other than the propellant or may optionally contain additional formulation excipients well known in the art such as surfactants eg oleic acid or lecithin and cosolvens eg ethanol. 
Pripravci u obliku aerosola mogu biti bez ekscipijensa, uz iznimku potisnog sredstva, ili po izboru mogu sadržavati dodatne ekscipijense dobro poznate u struci, primjerice surfaktante, npr. oleinsku kiselinu ili lecitin i kootapala, npr. etanol.
Use of nanoparticles or nanoparticles' aggregates for the preparation of a pharmaceutical composition for use in a method of altering or destroying target cells in an animal when said cells are exposed to ionizing radiations, wherein each nanoparticle or nanoparticles' aggregate consists of a metal oxide, wherein the density of said nanoparticle or the density of said nanoparticles' aggregate is of at least 7 g/cm3, and wherein each nanoparticle or nanoparticles' aggregate is covered with a biocompatible coating allowing the nanoparticle or nanoparticles' aggregate stability between pH 6.5 and 7.5 in a physiological fluid. 
PATENTNI ZAHTJEVI Uporaba nanočestica HfO, ili agregata nanočestica HfO, za pripremu farmaceutskog pripravka za uporabu u postupku mijenjanja ili uništavanja ciljnih stanica u životinje kada su spomenute stanice izložene ionizirajućim zračenjima, pri čemu je gustoća spomenutih nanočestica HfO, ili gustoća spomenutih agregata nanočestica HfO, barem 7 g/cm', i pri čemu je svaka nanočestica ili agregat nanočestica obložen biokompatibilnom ovojnicom koja daje nanočestici ili agregatu nanočestica stabilnost između pH 6,5 1 7,5 u fiziološkoj tekućini.
Comparable exposures via intravenous dosing in previous mouse studies did not result in death or gastrointestinal toxicity. 
Usporedivo izlaganje kod intravenskog unosa u prethodnim ispitivanjima na miševima nije uzrokovalo smrt niti gastrointestinalnu toksičnost.
The method according to one or more of the preceding claims 15 to 24, characterized in that the count of the elastomer thread (1a) used to provide said first rows of knitting (1) is comprised between 11.11 and 311.11 dtex. 
Postupak prema jednom ili više prethodnih zahtjeva 15 do 24, naznačen time, da se broj elastomernog konca (1a) upotrijebljenog za izradu spomenutih neparnih redova pletiva (1) nalazi između 11,11 i 311,11 deteksa.
either of the heavy chain variable domain CDR sets SEQ ID Nos:40, 41 and 42 or SEQ ID Nos:46, 47 and 42, and the light chain variable domain CDR set SEQ ID Nos:49, 50 and 51; 
bilo koji od CDR skupova varijabilne domene teškog lanca SEQ ID Nos:40, 41 i 42 ili SEQ ID Nos:46, 47 i 42, i skupa CDR varijabilne domene laganog lanca SEQ ID Nos:49, 50 i 51;
is hydrogen, halo, cyano, or trihalomethyl; and n is 1 or 2, provided that when n is 1, R3 is not hydrogen, and when n is 2, both R3 groups are not hydrogen; or a pharmaceutically acceptable salt and/or ester thereof, for use in treating congestive heart failure (CHF), heart failure, restenosis, asthma, obstructive airway disease, prostatic hyperplasia, priapism, erectile dysfunction, inflammatory pain, neuropathic pain, cancer pain, acute pain, chronic pain, irritable bowel syndrome, hypertonic lower oesophageal.sphincter, motility disorders, benign prostatic hyperplasia, attention deficit hyperactivity disorder, obesity, carcinoid tumors, teratocarcinoma, hyperprolactinemia or acromegaly. 
Ra je vodik, halo, cijano, ili trihalometil; i n je Lili 2, pod uvjetom da kad n je 1, Ra nije vodik, a kad n je 2, obje Ra skupine nisu vodik; ili njihova farmaceutski prihvatljiva sol ifili ester, za upotrebu u liječenju kongestivnog zatajivanja srca (CHF), srčanih zastoja, restenoze, asme, obstruktivne bolesti dišnih puteva, hiperplazije prostate, prijapizma, erektilne disfunkcije, upalne boli, neuropatske boli, karcinomske boli, akutno boli, kronično boli, sindroma razdražljivosti crijeva, hipertoničnog donjeg sfinktera jednjaka, HR P20100607 T1 motoričkih poremećaja, benigne hiperplazije prostate, poremećaja hiperaktivnosti i deficita pažnje, pretilosti, karcinoidnih tumora, teratokarcinoma, hiperprolaktinemije ili akromegalije.
(S)-2-(Diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinoline carboxylic acid having greater than 96% chemical purity. 
Natrijeva sol, naznačena time, da je od (S)-2-(difenilacetil)-l,2,3,4-tetrahidro- 6-metoksi-5-(fenilmetoksi)-3-izokinolin-karboksilne kiseline i njezini solvati, pri čemu se nalaze u amorfnom obliku ili u obliku kristalnog solvata.
Method of fuel for energetics production according to claims 5 to 7 characterized by that at the beginning of the process, at least one pressure vessel (1) is placed into the liquid heat carrier (8) and next pressure vessels (1) are stepwise additionally and/or alternatively placed here, while the generated gases are continuously drawn off, and this is done in such quantity of pressure vessels (1) and so long till the set quantity of the gas mixture is produced. 
Način za proizvodnju goriva za energetiku na temelju zahtjeva 5 do 7, naznačen time što se na početku procesa u tekući medij za prijenos topline (8) ubacuje bar jedna tlačna posuda (1) i ovdje se smještaju dodatne 1 / ili druge alternativne tlačne posude (1), pri čemu se kontinualno odvode nastali plinovi. To se izvodi u takvoj količini tlačnih posuda (1) i toliko dugo dok se ne proizvede određena količina plinovite smješe.
The invention further provides a composition comprising a boronic ester compound of formula (I), as described herein, and an ether solvent that has low miscibility with water. 
Kompozicija koja sadrži etersko otapalo koji ima nisku mješavost sa vodom i najmanje deset mola spoja estera organoborne kiseline formule (7): R2 R' BL OR
The pharmaceutical formulation of claim 15 for use in a method of treating prostate, lung or colon cancer, the method comprising administering to an individual an effective amount of the pharmaceutical formulation, wherein optionally the patient is administered a chemotherapeutic agent in combination with the antibody-drug conjugate compound, where the chemotherapeutic agent is selected from letrozole, cisplatin, carboplatin, taxol, paclitaxel, oxaliplatin, doxetaxel, 5-FU, leucovorin, lapatinib, and gemcitabine. 
16. Farmaceutska formulacija prema zahtjevu 15, naznačena time, da se upotrebljava u postupku liječenja raka prostate, raka pluća ili raka crijeva, pri čemu taj postupak obuhvaća davanje pojedincu učinkovitu količinu farmaceutske formulacije, gdje se po želji pacijentu daje kemoterapeutsko sredstvo u kombinaciji sa spojem konjugata protutijela-lijeka, dok je kemoterapeutsko sredstvo odabrano od sljedećih: letrozol, cisplatin, karboplatin, 10
This fibre structure is glued onto a woven base 11, or anchored thereto in another manner. 
Ova struktura vlakana je zalijepljena na tkanu bazu 11 ili je pričvršćena na nju na neki drugi način.
A compound according to claim 1, wherein R1 is a direct-bonded or oxygen-linked saturated, partially-saturated or unsaturated 5-, 6- or 7-membered monocyclic ring containing 1, 2, 3 or 4 atoms selected from N, O and S, but containing no more than one O or S. wherein the available carbon atoms of the ring are substituted by 0, 1 or 2 oxo or thioxo groups, wherein the ring is substituted by 0 or 1 R2 substituents, and the ring is additionally substituted by 0, 1, 2 or 3 substituents independently selected from halo, nitro, cyano, C1-4alkyl, OC1-4alkyl, OC1-4haloalkyl, NHC1-4alkyl, N(C1-4alkyl)C1-4alkyl and C1-4haloalkyl. 
Spoj prema patentnom zahtjevu 1, naznačen time što R' je direktno vezani ili kisikom vezani zasićeni, djelomično zasićeni ili nezasićeni 5-, 6- ili 7-člani monociklični prsten koji sadrži 1, 2, 3 ili 4 atoma izabrana od N, 0 1 S, ali koji ne sadrži više od jednog O ili S, pri čemu su dostupni atomi ugljika u prstenu supstituirani sa 0, 1 ili 2 okso ili tiokso grupe, gdje je prsten supstituiran sa 0 ili 1 R* supstituentom, i prsten je dodatno supstituiran sa 0, 1, 2 ili 3 supstituenta nezavisno izabrana od halo, nitro, cijano, C,agalkil, OC,4alkil, OCi4haloalkil, NHC,.galkil, N(C,4alkiDC,salkil 1 Ci. ahaloalkil.
providing an oligosaccharide comprising a first reactive group wherein the first reactive group is a hydrazide group or a carboxyl group; 
(a) osiguravanje oligosaharida koji sadrži prvu reaktivnu skupinu pri čemu je prva reaktivna skupina 5 hidrazidna skupina ili karboksilna skupina;
The method of claim 5, wherein selectively controlling the two or more subsets of thermoelectric coolers further comprises, in response to determining that the temperature of the chamber exceeds the upper threshold of the steady state range, increasing a current provided to the first subset of thermoelectric coolers. 
povećanje (1110) strujnog toka koji se dovodi do prvog TEH-podskupa, kao odgovor na određivanje stanja u kojem temperatura u komori prelazi gornju granicu raspona ravnomjernog stanja;
The system of claim 14, wherein an elongated guide extends radially into each slot in the slide member (192) to prevent rotation of the slide member (192) relative to the inner sleeve (190), wherein the elongated guides are preferably in the form of an elongated rod or pin. 
Sustav prema patentnom zahtjevu 11, naznačen time što se izdužena vodilica proteže radijalno u svaki utor u kliznom elementu (192) kako bi se spriječilo rotiranje kliznog elementa (192) u odnosu na unutarnji rukavac (190), pri čemu su izdužene vodilice poželjno u obliku izduženog klipa ili zatika.
Use according to any one of claims 1 and 4-15 or HfO2 nanoparticles or HfO2 nanoparticles' aggregates for use according to anyone of claims 2, 3 and 4-15, wherein said animal is a human. Pharmaceutical composition for use for altering or destroying target cells in an animal when said cells are exposed to ionizing radiations, wherein said pharmaceutical composition comprises HfO2 nanoparticles or HfO2 nanoparticles' aggregates and a pharmaceutically acceptable excipient, wherein the density of said HfO2 nanoparticles or the density of said HfO2 nanoparticles' aggregates is of at least 7 g/cm3, and wherein each nanoparticle or nanoparticles' aggregate is covered with a biocompatible coating allowing the nanoparticle or nanoparticles' aggregate stability between pH 6.5 and 7.5 in a physiological fluid. 
Farmaceutski pripravak za uporabu u mijenjanju ili uništavanju ciljnih stanica u životinje kada se te stanice izlože ionizirajućim zračenjima, gdje taj farmaceutski pripravak sadrži nanočestice ili aggregate nanočestica i farmaceutski prikladnu pomoćnu tvar, pri čemu se svaka nanočestica ili agregat nanočestica sastoji od metalnog oksida odabranog iz skupine koju čine CeO2, Tm2O3, HfO2, WO3 i PdO, gdje je gustoća te nanočestice ili agregata nanočestica najmanje 7,1 g/cm3 ako je metalni oksid CeO2, najmanje 8,3 g/cm3 ako je metalni oksid Tm2O3, najmanje 7,4 g/cm3 ako je metalni oksid HfO2, najmanje 7,2 g/cm3 ako je metalni oksid WO3, i najmanje 7,9 g/cm3 ako je metalni oksid PdO, i gdje je svaka nanočestica ili agregat nanočestica obložen biokompatibilnom ovojnicom koja daje nanočestici ili agregatu nanočestica stabilnost između pH 6.5 i 7.5 u fiziološkoj tekućini.
The user would then resume conventional control of the boat. 
Korisnik bi tada prešao na konvencionalni način upravljanja plovilom.
The sliding pocket door assembly according to claim 4, characterized in that said bracket (13) has a second arm (17) which is plate-shaped and is arranged adjacent to the vertical edge (18) of said door (2). 
Sklop džepnih kliznih vrata prema zahtjevu 4, naznačen time, da navedeni nosač (13) ima drugi krak (17) koji je pločastog oblika 1 raspoređen je susjedno uz vertikalni brid (18) od spomenutih vrata (2).
The result of the process steps described above is an arrangement 1 which then exists in particular in the form of a block or as a small plate in the form of a composite, as shown in FIGS. 1 and 2 . 
Gore opisan rezultat ovog koraka postupka je naprava 1, koja nakon toga postoji posebno u obliku bloka ili kao mala ploča u obliku kompozita, kako se vidi na slikama 1 i 2.
and wherein the polypeptides of formula I and the polypeptides of formula II form a cross-over light chain-heavy chain pair. 
i pri čemu polipeptidi s formulom I i polipeptidi s formulom II tvore prijelazni par laki lanac-teški lanac.
one or more aldehyde-releasing biocides and/or biocides with one or more aldehyde groups in an amount such that the total amount of aldehyde-releasing biocides and/or biocides with one or more aldehyde groups in the aqueous preparation is from 250 ppm to 5000 ppm, calculated relative to the weight of water in the preparation, and 
(a) jedan ili više biocida koji oslobađaju aldehid i/ili biocidi s jednom ili više aldehidnih skupina u količini tako da je ukupna količina biocida koji oslobađaju aldehid i/ili biocida s jednom ili više aldehidnih skupina u vodenom pripravku od 250 ppm do 5000 ppm, izračunato u odnosu na težinu vode u pripravku, te
The use of Claim 17 wherein the medical condition is a disorder of reduced motility of the gastrointestinal tract. 
Uporaba iz Patentnog zahtjeva 17, naznačena time, da je medicinsko stanje poremećaj smanjene pokretljivosti gastrointestinalnog trakta.
Once the pH is lowered from pH 7.2 to pH 4, the pyridine ring in the resin and the bound antibody become positively charged, due to charge repulsion, the immunoglobulins detaches and elutes from the column. 
Jednom kada se pH spusti sa pH 7.2 na pH 4, piridinski prsten u smoli 1 vezano protutijelo postaju pozitivno nabijeni, te se zbog odbijanja istoimenih naboja imunoglobulin odvaja i eluira sa kolone.
—NO2; is selected from the group consisting of: 
R'* je izabran iz grupe koju čine:
repeating steps (a) and (b), wherein the source basin is used as the recipient basin and the recipient basin is used as the source basin. 
(c) ponavljanje koraka (a) 1 (b), pri čemu se izvorni bazen koristi kao prijemni bazen i prijemni bazen se koristi kao izvorni bazen
The composition of any one of claims 1-17 for use in a method for inducing an immunogenic or protective response in an animal against one or more avian pathogens, said method comprising at least one administration of the composition. 
Vektor prema zahtjevu 10, naznačen time, da se upotrebljava u postupku induciranja imunosnog ili zaštitnog odgovora kod životinje protiv jednog ili više ptičjih patogena, pri čemu navedeni postupak obuhvaća najmanje jednu primjenu spomenutog sastava ili cjepiva.
The dermal micro-organ according to claim 2, wherein said length is 20-40 mm. The dermal micro-organ according to any one of claims 1-3, wherein at least one dimension of the cross-section is 0.5-3.5 mm. 
Genetički modificiran dermalni mikroorgan iz bilo kojeg od patentnih zahtjeva 1 - 3, naznačen time, da je najmanje jedan navedeni rekombinantni genski produkt prirodno proizveden u organu iz kojeg dermalni mikroorgan potječe.
The method according to Disclosure 44, wherein the disorder is cancer. 
Spoj za uporabu prema zahtjevu 13, naznačen time što je poremećaj rak.
inhibition of proliferation of cells expressing ErbB3; 
(ill) inhibicija proliferacije stanice koje eksprimiraju ErbB3;
wherein R3 is selected from ethylenediamine and cyclohexanediamine; wherein at least one of the one or more isolated monomeric platinum complexes is (Trans-1,2-cyclohexanediamine)(dihydrogen pyrophosphato)platinum(II). 
Pripravak za uporabu u postupku liječenja raka prema zahtjevu 1, naznačen time da izolirani monomerni kompleks platine je (trans-1,2-cikloheksandiamin)(dihidrogen pirofosfato)platina(II).
The electrochemical cell according to claim 9, wherein the anode is of a material comprising Li4Ti5O12, Li2Ti3O7, LixTiO2, TiO2, TiO2(OH)x and mixtures thereof. 
Elektrokemijski članak u skladu s patentnim zahtjevom 9, naznačen time što je anoda od materijala koji sadrži LuTi5042, LbT130;, LixTiO», TiO,, TiOx (OH), i njihove smjese.
The apparatus of any one of claims 7 to 10, wherein the coupling means (5) comprises a flexible cord, rope, line, cable, string, or a combination thereof. 
Sustav prema bilo kojem prethodnom zahtjevu, naznačen time što spojna sredstva (5) obuhvaćaju savitljivi kabel, uže, vod, kabel, konop ili njihovu kombinaciju.
The compound according to claim 13 or 14 or a pharmacologically acceptable salt thereof, wherein R5 or R7 represents a hydrogen atom. 
Spoj u skladu sa patentnim zahtjevom 13 ili 14 ili njegova farmakološki prihvatljiva sol, gdje R5 ili R7 predstavlja atom vodika.
Suitably when n is 2 or 3, each R5 group is the same or different halogeno atom, such as chloro or fluoro. 
Kada je n jednak 2 ili 3, svaka R* skupina je poželjno, isti ili različit atom halogena, npr. kloro ili fluoro.
An anticancer agent according to claim 16, wherein the cancer is any selected from lung cancer, breast cancer, prostate cancer, colon cancer, acute myeloid leukemia, malignant lymphoma, retinoblastoma, neuroblastoma, and sarcoma. 
Uporaba u skladu s patentnim zahtjevom 15, pri čemu je karcinom odabran između karcinoma pluća, karcinoma dojke, karcinoma prostate, karcinoma kolona, akutne mijeloične leukemije, malignog limfoma, retinoblastoma, neuroblastoma i sarkoma.
said bag-in-container made by the process comprising: 
Posuda s vrećicom u njoj napravljena postupkom koji obuhvaća:
Thereby the structure allows for easy placement of even large beverage containers. 
Time struktura omogućuje laku zamjenu čak i velikih spremnika za piće.
According to the preferred embodiment, the polynucleotide encoding the modified soluble FGF receptor Fc fusion has the sequence of SEQ ID NO: 1, or a sequence sharing at least 80% identity with SEQ ID NO: 1. 
Stanica-domaćin u skladu s patentnim zahtjevom 22, naznačena time što navedena nukleinska kiselina koja kodira modificiranu fuziju FGF receptora sadrži nukleinskokiselinski slijed koji je u najmanju ruku 80 % identičan s nukleinskokiselinskim slijedom iz SEQ ID NO:1.
An antibody or antigen-binding fragment thereof, which specifically binds human interleukin-6 receptor (hIL-6R) with a KD of 500 pM or less, as measured by surface plasmon resonance, wherein the heavy chain CDRs and the light chain CDRs comprise: 
Antitijelo ili njegov fragment koji se veže na antigen, koji se specifično veže na humani interleukin-6 receptor (hIL-6R) s konstantom KD od 500 pM ili manjom izmjereno površinskom plazmonskom rezonancijom, naznačeno time, da CDR teškog lanca i CDR lakog lanca sadržavaju:
The diafiltered SDS/IL-2 mixture, containing microaggregates, was tested for protein concentration (mg/ml) by dividing its absorbance at 280 nm by the IL-2 extinction coefficient (0.79). 
Diafiltrirana smjesa SDS/IL-2, koja sadrži mikroagregate, testirana je za koncentraciju proteina (mg/ml) dijeljenjem njegove apsorbancije pri 280 nm s IL-2 koeficijentom ekstincije (0,79).
Number of the 
Broj međunarodne objave:
a generator arranged to be driven by the turbine; 
generator kojeg pogoni turbina;
The aerosol composition may be free from excipients other than the propellant or may optionally contain additional formulation excipients well known in the art such as surfactants eg oleic acid or lecithin and cosolvens eg ethanol. 
Pripravci u obliku aerosola mogu biti bez ekscipijensa, uz iznimku potisnog sredstva, ili po izboru mogu sadržavati dodatne ekscipijense dobro poznate u struci, primjerice surfaktanto, npr. oleinsku kiselinu ili lecitin i kootapala, npr. etanol.
Splice sites are defined by the symbol “::”. 
Mjesta spajanja su definirana simbolom *.".
These cup-shaped body portions 130 and 140 are aligned along a vertical axis, which is also the axis of the above-mentioned bore 123 in the bottom wall 122 of the horizontal arm 121 of the base member 110 . 
Ti trupovi u obliku šalice 130 i 140 poravnati su uz okomitu os, koja je također i os gore navedenog provrta 123 u podnici 122 horizontalnog kraka 121 osnovnog elementa 110.
Such a regulation in cascade to the upstream direction, if applied either to the plant of the present invention or to the processes and plants according to other patents (in particular EP 0889762), with continuous casting directly connected to the rolling step without discontinuity, would unavoidably cause a variation of the casting speed, with negative consequences on the features relating to the slab quality in terms of surface homogeneity and internal features of the material. 
Takva regulacija u kaskadi u uzvodnom smjeru, ako se primjeni za postrojenje predstavljenog izuma ili postupke i postrojenja prema drugim patentima (posebno EP 0889762), s kontinuiranim lijevanjem izravno povezanim za valjanje bez prekida kontinuiranosti, neizbježno bi dovela do varijacija brzine lijevanja, s negativnim posljedicama za osobine kvalitete slaba u smislu homogenosti strukture i unutarnjih osobina materijala.
The apparatus according to claim 1, wherein at least one of the inflatable volume filling device and the inflatable adjustable stretching device comprises an expandable structure comprising a bellows adapted to take into account the fibrosis surrounding the device when implanted, such that the movement of the bellows is substantially un-affected of said fibrosis. 
Uređaj u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što uređaj dodatno ima najmanje jedno od sljedećeg: unutarnji izvor napajanja (70; 470), bežični prijemnik energije (205) za neinvazivno napajanje uređaja bežičnom energijom i prijemnik energije koji prima bežičnu energiju radi punjenja unutarnjeg izvora napajanja.
separating the alcoholic-caustic phase containing the trans-(-)-A9-tetrahydrocannabinol and the trans-(+)-A9-tetrahydrocannabinol from the first organic phase; 
razdvajanje alkoholno-kaustične faze koja sadrži trans-(-)-A9-tetrahidrokanabinol i trans-(+)-A9-tetrahidrokanabinol od prve organske faze;
providing: at least a first type of host cell expressing on its surface an extracellular domain of wild-type (wt) human PSMA comprising the amino acid sequence set forth in SEQ ID NO: 202, wherein said extracellular domain comprises the amino acid sequence set forth in SEQ ID NO: 447; 
vežuća domena, koja se može vezati na izvanstaničnu domenu mutiranog ljudskog PSMA s aminokiselinskim slijedom kao što je opisan u SEQ ID NO: 447, gdje su aminokiselinski ostaci na položajima 140, 169, 191, 308, 334, 339, 344, 624, 626, 716, 717 i 721 mutirani u odgovarajuće aminokiselinske ostatke PSMA divljeg tipa glodavca, no ne i na izvanstaničnu domenu PSMA glodavca;
an economizer line communicating with the headspace in the tank and adapted to direct vapor in the headspace toward the engine when a predetermined pressure in the tank is achieved and 
liniju (225) režima štednje koja je u vezi sa praznim prostorom u rezervoaru i prilagođena da usmjerava isparavanje u praznom prostoru prema motoru kada se u rezervoaru dostigne unaprijed utvrđeni pritisak;